Zacks: Sunshine Heart Inc (CHFS) Given $15.00 Consensus Target Price by Brokerages

Shares of Sunshine Heart Inc (NASDAQ:CHFS) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus price objective of $15.00 for the company, according to Zacks. Zacks has also assigned Sunshine Heart an industry rank of 170 out of 265 based on the ratings given to related companies.

Several brokerages have recently issued reports on CHFS. Zacks Investment Research lowered Sunshine Heart from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. ValuEngine raised Sunshine Heart from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 31st.

Shares of Sunshine Heart (CHFS) traded down $0.23 during trading hours on Friday, hitting $3.03. The stock had a trading volume of 354,040 shares, compared to its average volume of 652,289. Sunshine Heart has a 12-month low of $2.87 and a 12-month high of $111.40. The company has a market cap of $6.04, a price-to-earnings ratio of -0.02 and a beta of 2.34.

WARNING: “Zacks: Sunshine Heart Inc (CHFS) Given $15.00 Consensus Target Price by Brokerages” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/09/zacks-sunshine-heart-inc-chfs-given-15-00-consensus-target-price-by-brokerages.html.

Sunshine Heart Company Profile

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply